Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05215574
Title Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors NGM Biopharmaceuticals, Inc
Indications

Advanced Solid Tumor

Therapies

NGM831

NGM831 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.